lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France

17 Pages Posted: 29 Sep 2021

See all articles by Viet-Thi Tran

Viet-Thi Tran

Center for Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS- UMR 1153) - METHODS Team; Universite Paris Descartes; Universite Paris Descartes - Center for Clinical Epidemiology

Elodie Perrodeau

Université de Paris - Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité

Julia Saldanha

Université de Paris - Faculté de Médecine

Isabelle Pane

AP-HP - Centre d’Epidémiologie Clinique

Philippe Ravaud

Columbia University - Department of Epidemiology

More...

Abstract

Background: Long COVID is a complex multiorgan disorder that can affect patients’ lives severely. Recent reports suggest that symptoms improve after COVID-19 vaccination. 

Methods: We used data from the ComPaRe long COVID cohort to emulate a target trial evaluating the effect of vaccination among patients with long COVID who still had persistent symptoms at baseline. Vaccinated patients were matched to unvaccinated controls in a 1:1 ratio by their propensity scores. Outcomes, all measured at 120 days after baseline, include disease severity (long COVID ST, range 0-53), rate of complete remission (ie, disappearance of all symptoms), disease impact on patients’ lives (long covid IT, range 0-60), and the proportion of patients reporting an unacceptable symptom state. Vaccinated patients reported all adverse events occurring after vaccination in free text. 

Findings: In total, 455 patients were allocated to the vaccination group and 455 to the control group; 545 (60·1%) had confirmed infections, and 81 (8·9%) had been hospitalized during their acute COVID-19. By 120 days, vaccination reduced the long COVID symptoms (mean (SD) ST score in the vaccination group 13·0 (9·4) vs. 14·8 (9·8) in the control group; mean difference: -1·8, 95% CI -2·5 to -1·0) and doubled the rate of patients in complete remission (remission rate 16·6% vs 7·5%, HR: 1·97, 95% CI 1·23 to 3·15). Furthermore, vaccination reduced both disease impact on patients’ lives (mean (SD) IT score 24.3 (16·7) vs 27·6 (16·7); mean difference: -3·3, 95% CI -6·2 to -0·5) and the proportion of patients with an unacceptable symptom state (38.9% vs 46.4%, risk difference -7·5%, 95% CI -14·4 to -0·5). In the vaccination group, two (0·4%) patients reported serious adverse events leading to hospitalisation. 

Interpretation: COVID-19 vaccination lowers the severity and life impact of long COVID at 120 days among patients with persistent symptoms.

Funding Information: The authors received no specific funding for this work.

Declaration of Interests: The authors declare no competing interests and no financial associations that may be relevant or seen as relevant to the submitted manuscript. The authors have no association with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript.

Ethics Approval Statement: All patients provided online consent before participating in the cohort. The Institutional Review Board of Hôtel-Dieu Hospital, Paris, approved the study (IRB: 0008367).

Keywords: COVID-19, long COVID, COVID-19 vaccination, comparative effectiveness research, causal inference, target trial emulation

Suggested Citation

Tran, Viet-Thi and Perrodeau, Elodie and Saldanha, Julia and Pane, Isabelle and Ravaud, Philippe, Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France. Available at SSRN: https://ssrn.com/abstract=3932953 or http://dx.doi.org/10.2139/ssrn.3932953

Viet-Thi Tran (Contact Author)

Center for Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS- UMR 1153) - METHODS Team ( email )

1 Place du Parvis Notre Dame
Paris, 75006
France

Universite Paris Descartes ( email )

12, rue de l'Ecole de Médecine
Cedex 06
Paris, 75270
France

Universite Paris Descartes - Center for Clinical Epidemiology ( email )

France

Elodie Perrodeau

Université de Paris - Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité

Paris
France

Julia Saldanha

Université de Paris - Faculté de Médecine ( email )

Paris
France

Isabelle Pane

AP-HP - Centre d’Epidémiologie Clinique ( email )

Paris
France

Philippe Ravaud

Columbia University - Department of Epidemiology

722 West 168th Street
New York, NY 10032
United States

Click here to go to TheLancet.com

Paper statistics

Abstract Views
28,190
Downloads
3,627
PlumX Metrics